TELA Bio Inc

TELA

0.670USD

-0.076-10.19%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

TELA Bio Inc's Score

Industry at a Glance

Industry Ranking

85 / 208

Overall Ranking

211 / 4542

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

TELA Bio Inc Highlights

StrengthsRisks

TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 37.33% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 80.28M.

Overvalued

The company’s latest PE is -0.81, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 33.10M shares, decreasing 16.59% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.83M shares of this stock.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

2.250

Target Price

+201.57%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of TELA Bio Inc is 6.74, ranking 118 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 20.87M, representing a year-over-year increase of 18.24%, while its net profit experienced a year-over-year increase of 1.81%.

Score

Industry at a Glance

Previous score

6.74

Change

0



Financials

6.31

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.11

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.39

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.82

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of TELA Bio Inc is 8.30, ranking 30 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.81, which is -18.33% below the recent high of -0.66 and -505.89% above the recent low of -4.91.

Score

Industry at a Glance

Previous score

8.30

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 85/208

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of TELA Bio Inc is 8.00, ranking 61 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 4.00, with a high of 5.00 and a low of 1.25.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of TELA Bio Inc is 5.43, ranking 179 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 0.87 and the support level at 0.54, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.62

Change

-0.19

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of TELA Bio Inc is 7.00, ranking 81 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 75.61%, representing a quarter-over-quarter increase of 4.23%. The largest institutional shareholder is The Vanguard, holding a total of 1.83M shares, representing 4.18% of shares outstanding, with 14.21% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

EW Healthcare Partners

7.71M

+87.67%

Nantahala Capital Management, LLC

5.11M

--

North Run Capital, LP

3.68M

+85.75%

Lytton (Laurence W)

2.87M

+5.18%

SilverArc Capital Management, LLC

2.78M

+0.11%

Stonepine Capital Management, LLC

2.16M

+3.44%

The Vanguard Group, Inc.

Star Investors

1.80M

-5.84%

UBS Financial Services, Inc.

216.80K

-11.71%

Dafna Capital Management, LLC

1.44M

--

Perkins Capital Management, Inc.

833.93K

-4.79%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of TELA Bio Inc is 2.60, ranking 152 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.92. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. TELA Bio Inc’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

TELA Bio Inc

TELA

6.58 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Thermo Fisher Scientific Inc

TMO

8.39 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Bioventus Inc

BVS

8.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Anika Therapeutics Inc

ANIK

8.13 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Lantheus Holdings Inc

LNTH

8.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Edwards Lifesciences Corp

EW

8.05 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment